Premium
p53 immunoreactivity is uncommon in primary cutaneous lymphoma
Author(s) -
MCGREGOR J.M,
DUBLIN E.A.,
LEVISON D.A.,
MACDONALD D.M.,
SMITH N.P.,
WHITTAKER S.
Publication year - 1995
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1995.tb08667.x
Subject(s) - lymphomatoid papulosis , mycosis fungoides , lymphoma , pathology , medicine , cutaneous lymphoma , stage (stratigraphy) , cd30 , gene mutation , anaplastic lymphoma kinase , mutation , cancer research , gene , biology , paleontology , biochemistry , malignant pleural effusion , lung cancer
Summary p53 gene mutation appears to play an important role in the development of systemic lymphoma, and may be associated with tumour progression. Its role in cutaneous lymphoma is currently unknown. We examined p53 expression in 55 biopsies of cutaneous lymphoma, including patch‐, plaque‐ and tumour‐stage mycosis fungoides (MF), T‐ and B‐cell lymphoma and lymphomatoid papulosis. Strong, homogeneous p53 expression, thought to correlate most closely with p53 gene mutation, was seen in only three cases; in a plaque and tumour from a patiënt with tumour‐stage MF, in plaque‐stage MF in a patient without tumours, and in one case of CD30 + large‐cell anaplasüc lymphoma. These data suggest that p53 gene mutation is not a critical step in the development of the majority of primary cutaneous lymphomas.